Predictive diagnostics specialist Proteomics International Laboratories (ASX: PIQ) has appointed Eurobio Scientificto distribute its PromarkerD predictive test for diabetic kidney disease in France.
Eurobio Scientific is a leading French company in the fields of in vitro diagnostics (IVD), life sciences, and biotechnology, and specialises in developing, manufacturing, and distributing diagnostic products and services. It has a proven track record of marketing speciality diagnostic tests to public and private clinical laboratories, and is currently the leading independent distributor of IVDs in France.
“Eurobio Scientific's extensive distribution network across France ensures that our innovative PromarkerD predictive test can reach healthcare providers efficiently. Eurobio Scientific's strong relationships with key stakeholders, robust market knowledge and local expertise will drive demand for our test in this important market," Proteomics Managing Director, Dr Richard Lipscombe, said.
"PromarkerD is a cutting-edge diagnostic test specifically designed to predict the risk of diabetic kidney disease (DKD) in individuals with diabetes. It provides a significant advancement in diabetes management by enabling early detection and intervention, which are crucial for preventing or delaying the progression of this serious complication to end stage renal disease (dialysis or kidney transplant)."
In France an estimated 3.9 million people, or 8.6% of the adult population, live with type 2 diabetes1. The estimated direct costs of the disease in France exceeds EUR8.5 billion annually, and the country also has one of the highest rates of end-stage renal disease in Europe.
Eurobio Scientific will become the exclusive distributors for the PromarkerD predictive test following a sub- distribution agreement with Apacor Limited (UK) (Apacor), and under the terms of a master sub-distribution agreement between Apacor and Proteomics International.
Proteomics International has previously worked successfully with Apacor to achieve a Medtech Innovation Briefing (MIB) on the PromarkerD predictive test for diabetic kidney disease by the National Institute for Health and Care Excellence (NICE) in the United Kingdom.
MIBs, also known as 'NICE advice', are commissioned by the National Health Service (NHS) in the UK and designed to increase awareness of new technologies for planning and commissioning new innovation in the UK healthcare industry. Proteomics International is currently working with Apacor towards incorporation of PromarkerD in the NICE guidelines and on the roll-out of PromarkerD to the private market in the UK.
The term of the agreements with Eurobio Scientific and Apacor are for five years, extendable for additional periods of five years by mutual agreement and exclusive to France. Proteomics International will receive payment for each PromarkerD kit sold.
